• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    30 Stocks Moving In Tuesday's Mid-Day Session

    1/11/22 12:01:59 PM ET
    $ACCD
    $ACI
    $ANF
    $BARK
    Business Services
    Consumer Discretionary
    Food Chains
    Consumer Staples
    Get the next $ACCD alert in real time by email

    Gainers

    • TSR, Inc. (NASDAQ:TSRI) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year.
    • Accolade, Inc. (NASDAQ:ACCD) gained 27.3% to $24.36 after the company reported Q3 earnings results and raised FY22 sales guidance.
    • Nuverra Environmental Solutions, Inc. (NYSE:NES) shares jumped 22.6% to $2.8450.
    • BARK, Inc. (NYSE:BARK) gained 18% to $4.25. The company said it expects Q3 sales of $140 million, versus analysts’ estimates of $137.3 million. BARK co-founder and executive chairman Matt Meeker will cecome CEO.
    • Nutriband Inc. (NASDAQ:NTRB) jumped 17.2% to $7.08. Nutriband and Kindeva Drug Delivery, on Monday, signed a feasibility agreement to develop AVERSA Fentanyl, an abuse deterrent fentanyl patch.
    • Veru Inc. (NASDAQ:VERU) surged 17% to $6.25. Veru, on Monday, said that its Enobosarm was granted fast track designation by the FDA.
    • Cingulate Inc. (NASDAQ:CING) jumped 15% to $2.82. Aegis Capital initiated coverage on Cingulate with a Buy rating and announced a price target of $9.
    • Shake Shack Inc. (NYSE:SHAK) gained 13.3% to $77.35 after the company issued Q4 and FY21 sales guidance above guidance.
    • Molecular Partners AG (NASDAQ:MOLN) rose 12.6% to $24.22. Molecular Partners shares jumped over 30% on Monday after the company, and Novartis, reported topline data from the Phase 2 study for ensovibep, a DARPin antiviral therapeutic for COVID-19.
    • Cognition Therapeutics, Inc. (NASDAQ:CGTX) gained 12.4% to $6.74. The company, on Monday, issued summary of its 2021 accomplishments and outlined upcoming milestones anticipated in the year ahead.
    • CVD Equipment Corporation (NASDAQ:CVV) jumped 11.8% to $4.54. CVD Equipment said orders exceeded $5 million in Q4 and $21 million overall for FY21.
    • Quantum Computing, Inc. (NASDAQ:QUBT) gained 11.6% to $3.26.
    • Micro Focus International plc (NYSE:MFGP) climbed 11.6% to $6.30.
    • Future FinTech Group Inc. (NASDAQ:FTFT) rose 11.5% to $1.16 after dropping 10% on Monday. Future FinTech recently named Ola Lind as Chief Strategy Officer.
    • Micro Focus International plc (NYSE:MFGP) rose 11.3% to $6.28.
    • Sonendo, Inc. (NYSE:SONX) rose 11.2% to $6.27 after the company issued strong sales forecast for the fourth quarter.
    • Tivic Health Systems, Inc. (NASDAQ:TIVC) surged 10.6% to $3.13.
    • OneSmart International Education Group Limited (NYSE:ONE) gained 9.1% to $0.2120. OneSmart International Education Group received notification from NYSE regarding delayed Form 20-F filing.
    • Cellectis S.A. (NASDAQ:CLLS) gained 7.5% to $8.51. Cellectis' licensed partner, Allogene Therapeutics, announced removal of FDA clinical hold on their clinical trials.
    • Illumina, Inc. (NASDAQ:ILMN) climbed 7.5% to $389.34 as the company issued strong sales forecast for 2022, and also reported four partnership agreements.
    • Inari Medical, Inc. (NASDAQ:NARI) rose 5.3% to $89.25 after the company issued strong Q4 and FY21 sales guidance.
    • Abercrombie & Fitch Co. (NYSE:ANF) rose 5.3% to $34.06 as the company issued an update on its forecast for the 2021 fiscal year. The company said it sees preliminary FY21 net sales rising 19% to 20% from 2020. The company also projects Q4 net sales up in the range of 4% to 6% from 2020.

    Check out these big penny stock gainers and losers

    Losers

    • Huadi International Group Co., Ltd. (NASDAQ:HUDI) shares fell 57.4% to $11.67.
    • Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) shares dipped 25.7% to $7.35.
    • Bone Biologics Corporation (NASDAQ:BBLG) fell 21.9% to $4.21. Bone Biologics shares surged 57% on Monday following the company's presentation at the HC Wainwright BioConnect Virtual Conference.
    • Pacific Biosciences of California, Inc. (NASDAQ:PACB) fell 12.6% to $14.49 after the company issued Q4 and FY21 sales guidance below estimates. The company announced preliminary revenue of approximately $36 million for its fourth quarter, below the consensus estimate of $36.58 million.
    • Albertsons Companies, Inc. (NYSE:ACI) dropped 10.8% to $28.45. Albertsons Companies reported upbeat earnings for its third quarter and boosted its FY21 forecast.
    • Esports Technologies, Inc. (NASDAQ:EBET) fell 8.7% to $14.63.
    • Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) shares declined 8.7% to $3.05.
    • Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) fell 8.4% to $2.72. The FDA, on Monday, notified Reviva Pharmaceuticals that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia.
    Get the next $ACCD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACCD
    $ACI
    $ANF
    $BARK

    CompanyDatePrice TargetRatingAnalyst
    Shake Shack Inc.
    $SHAK
    4/24/2026$120.00Buy
    Guggenheim
    Quantum Computing Inc.
    $QUBT
    4/20/2026$20.00Outperform
    Northland Capital
    Shake Shack Inc.
    $SHAK
    4/10/2026$120.00Neutral → Outperform
    Mizuho
    Shake Shack Inc.
    $SHAK
    3/31/2026$101.00Underperform → Neutral
    BofA Securities
    Shake Shack Inc.
    $SHAK
    3/30/2026$124.00Outperform
    BNP Paribas Exane
    Abercrombie & Fitch Company
    $ANF
    3/26/2026$108.00Buy
    Needham
    Shake Shack Inc.
    $SHAK
    3/9/2026$118.00Outperform
    Wolfe Research
    Shake Shack Inc.
    $SHAK
    3/6/2026$125.00Buy
    DA Davidson
    More analyst ratings

    $ACCD
    $ACI
    $ANF
    $BARK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gottlieb Scott bought $23,562 worth of shares (200 units at $117.81), increasing direct ownership by 2% to 12,723 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/11/26 4:04:54 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:19 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACCD
    $ACI
    $ANF
    $BARK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ENTADFI issued to VERU INC

    Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination

    12/13/21 8:12:46 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACCD
    $ACI
    $ANF
    $BARK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Shake Shack with a new price target

    Guggenheim initiated coverage of Shake Shack with a rating of Buy and set a new price target of $120.00

    4/24/26 8:06:57 AM ET
    $SHAK
    Restaurants
    Consumer Discretionary

    Northland Capital initiated coverage on Quantum Computing with a new price target

    Northland Capital initiated coverage of Quantum Computing with a rating of Outperform and set a new price target of $20.00

    4/20/26 8:28:07 AM ET
    $QUBT
    Computer Software: Prepackaged Software
    Technology

    Shake Shack upgraded by Mizuho with a new price target

    Mizuho upgraded Shake Shack from Neutral to Outperform and set a new price target of $120.00

    4/10/26 8:28:04 AM ET
    $SHAK
    Restaurants
    Consumer Discretionary

    $ACCD
    $ACI
    $ANF
    $BARK
    SEC Filings

    View All

    Amendment: SEC Form 10-K/A filed by Creative Medical Technology Holdings Inc.

    10-K/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)

    4/24/26 4:45:24 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form DEFA14A filed by Pacific Biosciences of California Inc.

    DEFA14A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

    4/23/26 4:43:04 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEF 14A filed by Pacific Biosciences of California Inc.

    DEF 14A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

    4/23/26 4:40:38 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ACCD
    $ACI
    $ANF
    $BARK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model

    Ticker Symbol to Change from TIVC to VBIO Effective April 28, 2026; Company Advancing Entolimod™ Toward BARDA Funding and Strategic National Stockpile Procurement While Velocity Bioworks CDMO Builds Independent Revenue BaseSAN ANTONIO, April 23, 2026 /PRNewswire/ -- Tivic Health Systems, Inc. (NASDAQ:TIVC) today announced it is changing its corporate name to Valion Bio, Inc. and its Nasdaq ticker symbol from TIVC to VBIO, effective at market open on Tuesday, April 28, 2026. The CUSIP number for the company's common stock will remain unchanged. The rebrand is not merely cosmetic.

    4/23/26 4:05:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Quantum Computing Inc. Announces Deployment-Ready NeuraWave, a Photonic Computing Platform for Real-time AI Inference at the Edge

    Designed for Applications in Telecommunications, Autonomous Vehicles, Robotics, Healthcare and Other Markets Requiring Real-Time InferenceHOBOKEN, N.J., April 23, 2026 /PRNewswire/ -- Quantum Computing Inc. ("QCi" or the "Company") (NASDAQ:QUBT) an innovative, quantum optics and integrated photonics technology company, today announced that NeuraWave, its next-generation photonic reservoir computing platform first debuted at SC25, is now deployment-ready.  NeuraWave is designed to enable faster, energy-efficient artificial intelligence (AI) inference and advanced signal processing applications at the edge.Conventional AI systems rely on power‑hungry digital processors. NeuraWave uses hybrid p

    4/23/26 8:30:00 AM ET
    $QUBT
    Computer Software: Prepackaged Software
    Technology

    Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine's Potential Across Multiple Neuropsychiatric Indications

    CUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat hosted by A.G.P. Equity Research Analyst James Molloy on Monday, April 27, 2026 at 11:00 AM ET. The fireside chat will highlight the recent developments from Reviva's clinical stage drug candidate brilaroxazine and upcoming clinical, regulatory

    4/23/26 8:00:00 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACCD
    $ACI
    $ANF
    $BARK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Morris Susan exercised 114,141 shares at a strike of $17.90 and covered exercise/tax liability with 49,206 shares, increasing direct ownership by 7% to 1,053,547 units (SEC Form 4)

    4 - Albertsons Companies, Inc. (0001646972) (Issuer)

    4/23/26 7:55:14 PM ET
    $ACI
    Food Chains
    Consumer Staples

    Chief Tech &Transformation Off Dhanda Anuj exercised 71,253 shares at a strike of $17.90 and covered exercise/tax liability with 34,601 shares, increasing direct ownership by 11% to 375,276 units (SEC Form 4)

    4 - Albertsons Companies, Inc. (0001646972) (Issuer)

    4/23/26 7:54:18 PM ET
    $ACI
    Food Chains
    Consumer Staples

    President & CFO Mccollam Sharon exercised 114,425 shares at a strike of $17.90 and covered exercise/tax liability with 43,260 shares, increasing direct ownership by 15% to 558,051 units (SEC Form 4)

    4 - Albertsons Companies, Inc. (0001646972) (Issuer)

    4/23/26 7:53:47 PM ET
    $ACI
    Food Chains
    Consumer Staples

    $ACCD
    $ACI
    $ANF
    $BARK
    Leadership Updates

    Live Leadership Updates

    View All

    Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

    BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors. Further, the Company announced that it plans to change its name to Quantum Cyber and change its Nasdaq ticker symbol to QUCY, beginning on March 12, 2026. The permanent election of Mr. Liscouski and the change of Company name will become effective at the Company's extraordinary general meeting, being planned for April 2026. The Company will begin doing business as Quantum Cyber and trading under the symbol QUCY beginning on M

    3/11/26 7:30:00 AM ET
    $MYNZ
    $QUBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Defining Wellness Centers Names Bill Morrison Chief Financial Officer

    Experienced Healthcare Executive Joins Leadership Team to Support Continued Growth Backed by Fulcrum Equity PartnersJACKSON, Miss., March 9, 2026 /PRNewswire/ -- Defining Wellness Centers (www.definingwellness.com) today announced that veteran healthcare executive Bill Morrison has joined the organization as Chief Financial Officer. Morrison brings more than 25 years of experience helping scale healthcare and behavioral health companies and will oversee the company's financial strategy during a period of continued growth backed by Atlanta-based growth equity firm Fulcrum Equity Partners.

    3/9/26 9:17:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Quantum Computing Inc. Completes Acquisition of NuCrypt to Advance Quantum Communications Commercialization

    HOBOKEN, N.J., March 5, 2026 /PRNewswire/ -- Quantum Computing Inc. ("QCi" or the "Company") (NASDAQ:QUBT), an innovative, quantum optics and integrated photonics technology company, today announced the completion of its acquisition of NuCrypt, LLC ("NuCrypt"), a quantum communications technology company, in a transaction valued at $5 million, to be paid in a combination of cash and shares of QCi common stock (the "Transaction").The acquisition helps establish quantum communications as an important commercialization vertical within QCi's broader quantum technology strategy. By integrating NuCrypt's suite of quantum communications systems and products, QCi expects to advance its technology ro

    3/5/26 8:30:00 AM ET
    $QUBT
    Computer Software: Prepackaged Software
    Technology

    $ACCD
    $ACI
    $ANF
    $BARK
    Financials

    Live finance-specific insights

    View All

    PacBio to Report First Quarter 2026 Financial Results on May 7, 2026

    MENLO PARK, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2026 financial results on Thursday, May 7, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). The call will be webcast and may be accessed on PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, May 7, 2026, at 4:30 p.m. ET (1:30 p.m. PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/ Toll-free: 1-888-349-0136 International: 1-412-317-0459 About PacBio PacBio (NASDAQ:PACB) is a premier life science technology company that designs, develops, and manufactures a

    4/16/26 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Albertsons® Companies, Inc. Reports Fourth Quarter and Full Year Results

    Announces 13% Increase in Common Stock Dividend Increases Remaining Share Repurchase Authorization to $2 billion Provides Fiscal 2026 Outlook Albertsons® Companies, Inc. (NYSE:ACI) (the "Company") today reported results for the fourth quarter of fiscal 2025 and full year fiscal 2025, which ended Feb. 28, 2026 and included 13 and 53 weeks, respectively. Fourth Quarter of Fiscal 2025 Highlights Identical sales increased 0.7% Digital sales increased 16% Loyalty members increased 12% to 51.2 million Net loss of $(481) million, or $(0.94) per share, inclusive of the $600 million charge, net of tax, or $(1.18) per share, related to the Opioid Settlement Framework (as defined herei

    4/14/26 7:30:00 AM ET
    $ACI
    Food Chains
    Consumer Staples

    Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026

    SAN DIEGO, April 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2026 following the close of market on Thursday, April 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, April 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's

    4/9/26 4:30:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ACCD
    $ACI
    $ANF
    $BARK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/26/24 8:27:01 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials